National Research Corporation
NASDAQ:NRCMedical - Healthcare Information Services
+$0.07 today
- Market cap
- $555.16M
- Beta
- 0.40
- P/E (TTM)
- 43.0
- EPS (TTM)
- $0.41
- Dividend yield
- 3.14%
Volume 0.09M
Average 0.11M
NRC Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
National Research CorporationNASDAQ: NRC
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow grows, but more slowly than its trailing trend
Q1 FY2026 financing cash flow of $6.94M (cash outflow) rose 28.7% year over year, behind the +86.9% change in trailing-twelve-month financing cash flow. Sequentially, it rose 67.7% from the prior quarter. Over 3 fiscal years it compounded at -34.2% a year.
Context
- Financing cash flow amounted to 11.5% of revenue in FY2025, down 0.2 pp from a year earlier.
- Financing cash flow grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +28.7% toward the trailing-twelve-month pace of +86.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (15.84M) USD
- Year-over-year change
- +5.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (15.84M) | +5.5% |
| FY2024 | 2024-12-31 | (16.76M) | +58.8% |
| FY2023 | 2023-12-31 | (40.71M) | +26.8% |
| FY2022 | 2022-12-31 | (55.58M) | -206.0% |
| FY2021 | 2021-12-31 | (18.16M) | — |
Financing Cash Flow vs competitors
How NRC compares with its peers on the latest reported figures
- NRC's LTM Mar 2026 financing cash flow of $17.39M is the 7th largest of the 8 companies compared; the peer median is $5.83M.
- Its year-over-year change of +86.9% is the 4th highest of 8, against a peer median of -50.7%.
- Financing cash flow amounts to 12.5% of revenue for NRC, versus a peer median of 13.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $231.07M | -258.1% | +348.5% | 76.4% | |
| LTM Mar 2026 | $51.96M | -65.2% | +78.1% | 21.8% | |
| LTM Apr 2026 | $49.45M | +570.9% | — | 10.0% | |
| LTM Mar 2026 | $46.34M | +308.7% | — | 57.1% | |
| LTM Mar 2026 | $42.59M | +782.6% | +15.2% | 13.7% | |
CTEVClaritev Corporation | LTM Mar 2026 | $28.15M | -56.0% | — | 2.9% |
| LTM Mar 2026 | $17.39M | +86.9% | -34.2% | 12.5% | |
| LTM Mar 2026 | $5.83M | -50.7% | -9.8% | 4.7% | |
| Peer median (excluding NRC) | $5.83M | -50.7% | +46.7% | 13.7% | |
Competitors are the stored peer set for NRC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 37.47M | 31.8M | 30.97M | 24.78M | 11.6M |
| Depreciation & Amortization | 6.37M | 5.28M | 5.9M | 6.02M | 7.62M |
| Deferred Income Tax | 33K | (1.24M) | (717K) | (406K) | 2.45M |
| Stock-Based Compensation | 623K | 1.2M | 935K | 284K | 3.31M |
| Change in Working Capital | 1.84M | (3.35M) | 1.03M | 3.84M | 916K |
| Accounts Receivables | 343K | (733K) | 2.08M | 1.76M | (53K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 4K | (589K) | 184K | (108K) | 170K |
| Other Working Capital | 1.49M | (2.03M) | (1.24M) | 2.19M | 799K |
| Other Non-Cash Items | 7K | 2.58M | (102K) | 100K | 545K |
| Operating Cash Flow | 46.34M | 36.27M | 38.11M | 34.63M | 26.45M |
| Capital Expenditures | (5.51M) | (9.84M) | (15.78M) | (15.45M) | (10.71M) |
| Acquisitions (Net) | (3M) | 0 | 0 | (4.83M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 1K | 0 | 0 |
| Investing Cash Flow | (8.51M) | (9.84M) | (15.78M) | (20.28M) | (10.71M) |
| Debt Repayment | (4.59M) | (4.77M) | 14.18M | 25.99M | 16.11M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 132K |
| Common Stock Repurchased | (4.14M) | (27.62M) | (19.1M) | (30.95M) | (20.18M) |
| Dividends Paid | (9.16M) | (20.96M) | (36.37M) | (11.45M) | (10.98M) |
| Other Financing Activities | (275K) | (2.04M) | 576K | (359K) | (923K) |
| Financing Cash Flow | (18.16M) | (55.58M) | (40.71M) | (16.76M) | (15.84M) |
| Effect of Forex Changes | 3K | (182K) | (1K) | 0 | 0 |
| Net Change in Cash | 19.67M | (29.34M) | (18.37M) | (2.42M) | (94K) |
| Free Cash Flow | 40.83M | 26.43M | 22.33M | 19.18M | 15.74M |
National Research Corporation
NASDAQ:NRC
Intrinsic Alpha fair value
Locked
Current Price
$26.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.